Course Director

Daniel Pallin, MD, MPH
Daniel Pallin, MD, MPH

Harvard Medical School
Brigham and Women’s Hospital
Boston, Massachusetts


Douglas B. Johnson
Douglas B. Johnson, MD, MSCI

Vanderbilt University Medical Center
Nashville, Tennessee

Activity Description and Educational Objectives

In this activity, an emergency medicine and an oncology expert report on the latest information on immune-related adverse effects (irAEs) via an interactive, practical, and highly visual format. The expert faculty provides emergency medicine professionals with a foundational understanding of cancer immunotherapies and how they work, as well as the mechanisms underlying the development of the unique spectrum of irAEs, and share practical guidance on evaluating, diagnosing, and managing these toxicities in the emergency department setting collaboratively with oncologists.

Upon completion of this activity, participants will be able to:
  • Summarize the basic principles of harnessing the human immune system in the treatment of cancer, as well as the mechanistic aspects of immune checkpoint inhibition in cancer therapy and development of immune-related adverse effects (irAEs) associated with immunotherapies
  • Describe the spectrum of the more and less common irAEs associated with the immune checkpoint inhibitors and combinations, including incidence and presentation, with emphasis on those most likely to be encountered by emergency medicine (EM) professionals in the emergency department (ED)
  • Discuss the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED
  • Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology

Target Audience

This activity has been designed to meet the educational needs of emergency medicine physicians, nurses, and other professionals involved in managing patients experiencing oncologic emergencies presenting to emergency departments.

Nursing Education Purpose Statement

The purpose of this activity is to improve the knowledge and competence of nurses concerning recognition, diagnosis, and management of adverse effects associated with cancer immunotherapies in patients with malignant tumors presenting to emergency departments.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME/MOC/CE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/MOC/CE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: November 21, 2018 - November 20, 2019
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC/CE activity during the past 12 months.

Course Director and Moderator

Daniel Pallin, MD, MPH
Assistant Professor of Emergency Medicine
Harvard Medical School
Research Director, Department of Emergency Medicine
Brigham and Women’s Hospital
Boston, Massachusetts

Daniel Pallin, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Other Financial or Material Support from Chairing a Medical Advisory Board panel for Portola Pharmaceuticals, Inc. Site Principal Investigator for JDP Therapeutics Inc.; Melinta Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer, Inc.; and Portola Pharmaceuticals, Inc.

Daniel Pallin, MD, MPH, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Agents to treat side effects of cancer immunotherapies.


Douglas B. Johnson, MD, MSCI
Director, Melanoma Research Program
Division of Hematology-Oncology
Assistant Professor of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee

Douglas B. Johnson, MD, MSCI, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Bristol-Myers Squibb and Incyte Corporation.
Advisory Board for Array BioPharma; Bristol-Myers Squibb; Genoptix, Inc.; Incyte Corporation; and Merck & Co., Inc.

Douglas B. Johnson, MD, MSCI, does not intend to discuss any non-FDA-approved or investigational use of any products/devices.

CME Reviewer

Siyang Leng, MD

Siyang Leng, MD, has no financial interests/relationships or affiliations in relation to this activity.

Nurse Reviewer

Amita B. Patel, MSN, RN, AOCNP, NP-C

Amita B. Patel, MSN, RN, AOCNP, NP-C, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education

Kadrin Wilfong, MD, has no financial interests/relationships or affiliations in relation to this activity.


The information provided at this CME/MOC/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement
ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Individual or aggregated participant data may be shared with the funder of the activity.


Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.5 contact hours.


This CME/MOC/CE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.


This activity is supported by an independent educational grant from AstraZeneca.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME/MOC/CE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2018, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.